CUTOMYA
DEAD

Serial Number

87299360

Owner

ALLERGAN SALES, LLC

Filing Date

Jan 12, 2017

Add to watchlist:

No watchlists yet
View on USPTO

CUTOMYA Trademark

Serial Number: 87299360

CUTOMYA is a trademark filed by ALLERGAN SALES, LLC on January 12, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN SALES, LLC (490 trademarks)

5 GIRALDA FARMS
MADISON, NJ 07940

Entity Type: 16

Trademark Details

Filing Date

January 12, 2017

Registration Date

Not Registered

Published for Opposition

May 2, 2017

Goods & Services

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Feb 22, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Feb 21, 2022 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 21, 2021 EXRA
SOU EXTENSION 5 GRANTED
Jul 20, 2021 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 19, 2021 AITU
SOU EXTENSION 5 FILED
Jul 12, 2021 EXT5
SOU TEAS EXTENSION RECEIVED
Jul 12, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 9, 2021 EXRA
SOU EXTENSION 4 GRANTED
Jan 7, 2021 EX4G
SOU EXTENSION 4 FILED
Jan 7, 2021 EXT4
SOU TEAS EXTENSION RECEIVED
Jan 7, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 30, 2020 EXRA
SOU EXTENSION 3 GRANTED
Jun 26, 2020 EX3G
SOU EXTENSION 3 FILED
Jun 26, 2020 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 26, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 11, 2020 EXRA
SOU EXTENSION 2 GRANTED
Jan 9, 2020 EX2G
SOU EXTENSION 2 FILED
Jan 9, 2020 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 9, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 11, 2019 EXRA
SOU EXTENSION 1 GRANTED
Jun 7, 2019 EX1G
SOU EXTENSION 1 FILED
Jun 7, 2019 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 7, 2019 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 15, 2019 NOAM
TTAB RELEASE CASE TO TRADEMARKS
Dec 3, 2018 TMBN
OPPOSITION TERMINATED NO. 999999
Dec 3, 2018 OP.T
OPPOSITION DISMISSED NO. 999999
Dec 3, 2018 OP.D
OPPOSITION INSTITUTED NO. 999999
Aug 30, 2017 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
May 31, 2017 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 2, 2017 NPUB
PUBLISHED FOR OPPOSITION
May 2, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 12, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 22, 2017 CNSA
ASSIGNED TO EXAMINER
Mar 11, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 19, 2017 NWOS
NEW APPLICATION ENTERED
Jan 16, 2017 NWAP